| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Apical oligopeptide transporters. Valylvaline is a stereochemistry-dependent substrate and inhibitor of apical oligopeptide transporters. It undergoes apical intracellular accumulation in human intestinal cells via carrier-mediated transport. The compound inhibits the uptake of Cephalexin through interaction with transporters. It is also a metabolite of Mycoplasma genitalium.
|
|---|---|
| ln Vitro |
Valylvaline is a substrate and inhibitor of apical oligopeptide transporters. It undergoes apical intracellular accumulation in human intestinal cells via carrier-mediated transport. The compound inhibits the uptake of Cephalexin through interaction with transporters. It is a hydrophobic, nanotube-forming compound.
|
| ln Vivo |
Valylvaline is a metabolite of Mycoplasma genitalium. It has been reported to exist in Brassica napus, ginseng, and other organisms. The compound is used for protein synthesis and can be used for the synthesis of important compounds such as Poststatin.
|
| Enzyme Assay |
Valylvaline is evaluated in cell-free assays for its ability to inhibit oligopeptide transporters. Transport assays are performed using membrane preparations or purified transporter proteins. The compound's interaction with transporters is assessed by measuring its ability to inhibit the uptake of substrates such as Cephalexin.
|
| Cell Assay |
Valylvaline is assessed in cell-based assays using human intestinal cells. Cells are treated with Valylvaline, and intracellular accumulation is measured to assess carrier-mediated transport. The compound's ability to inhibit the uptake of Cephalexin is assessed. The compound is a stereochemistry-dependent substrate and inhibitor of apical oligopeptide transporters.
|
| Animal Protocol |
Valylvaline is administered in animal models to evaluate its effects on oligopeptide transport and metabolism. However, specific animal study protocols are not well-documented. The compound is a metabolite and is used for research purposes.
|
| ADME/Pharmacokinetics |
Valylvaline has a molecular weight of 216.28 and a molecular formula of C10H20N2O3. It has a CAS number of 3918-94-3. The compound is a dipeptide composed of two L-valine residues. It is a hydrophobic, nanotube-forming compound. It is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for Valylvaline. The compound is for research use only and is not intended for human therapeutic use. It is an endogenous metabolite and a dipeptide, suggesting a favorable safety profile. However, specific toxicity studies have not been well-characterized.
|
| Additional Infomation |
Val-Val is a dipeptide composed of two L-valine residues. It is a metabolite of Mycoplasma genitalium and is functionally related to L-valine. Val-Val has been reported to exist in Brassica napus, ginseng, and other organisms with relevant data.
Valylvaline (Val-Val, H-Val-Val-OH) is a dipeptide composed of two L-valine residues linked by an amide bond. It has a molecular weight of 216.28 and a molecular formula of C10H20N2O3. The compound has a CAS number of 3918-94-3. It is a metabolite of Mycoplasma genitalium and functions as a stereochemistry-dependent substrate and inhibitor of apical oligopeptide transporters. It undergoes apical intracellular accumulation in human intestinal cells via carrier-mediated transport. The compound is for research use only and has not been approved for clinical use. |
| Molecular Formula |
C10H20N2O3
|
|---|---|
| Molecular Weight |
216.28
|
| Exact Mass |
216.147
|
| Elemental Analysis |
C, 55.53; H, 9.32; N, 12.95; O, 22.19
|
| CAS # |
3918-94-3
|
| PubChem CID |
107475
|
| Appearance |
Solid powder
|
| Density |
1.084g/cm3
|
| Boiling Point |
411.6ºC at 760 mmHg
|
| Flash Point |
202.7ºC
|
| Index of Refraction |
1.483
|
| LogP |
1.286
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
15
|
| Complexity |
239
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(C)C(C(=O)NC(C(C)C)C(=O)O)N
|
| InChi Key |
KRNYOVHEKOBTEF-YUMQZZPRSA-N
|
| InChi Code |
InChI=1S/C10H20N2O3/c1-5(2)7(11)9(13)12-8(6(3)4)10(14)15/h5-8H,11H2,1-4H3,(H,12,13)(H,14,15)/t7-,8-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoic acid
|
| Synonyms |
Val-val; Valylvaline
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~9.52 mg/mL (~44.02 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.95 mg/mL (4.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 9.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.95 mg/mL (4.39 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 9.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.95 mg/mL (4.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6236 mL | 23.1182 mL | 46.2364 mL | |
| 5 mM | 0.9247 mL | 4.6236 mL | 9.2473 mL | |
| 10 mM | 0.4624 mL | 2.3118 mL | 4.6236 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06387771 | RECRUITING | Drug:Tolcapone | Schizophrenia | Clinica Universidad de Navarra, Universidad de Navarra |
2014-09-22 | Phase 2 |
| NCT05200897 | RECRUITING | Device:Transdermal trigeminal electrical neuromodulation(Cefaly) |
Alzheimer Disease Amyloid Insomnia Mild Cognitive Impairment |
Saint Vincent's Hospital,Korea | 2021-11-03 | Not Applicable |
| NCT02146963 | COMPLETED | Alcohol Dependence | Centre Hospitalier Esquirol | 2014-05 | ||
| NCT02949934 | COMPLETED | Drug:Tolcapone Drug:Placebo |
Alcohol Use Disorder | Medical University of South Carolina |
2016-05-01 | Phase 2 |
| NCT06387771 | RECRUITING | Drug:Tolcapone | Schizophrenia | Clinica Universidad de Navarra, Universidad de Navarra |
2014-09-22 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
